Price Alert

Cardiff Oncology Inc. (CRDF)

NASDAQ: CRDF · Real-Time Price · USD

2.06

-0.02 (-0.96%)

At close: Sep 12, 2025, 12:55 PM

-0.96% (1D)

Bid	2.05
Market Cap	136.71M
Revenue (ttm)	546K
Net Income (ttm)	-51.02M
EPS (ttm)	-0.87
PE Ratio (ttm)	-2.36
Forward PE	-2.34
Analyst	Buy

Ask	2.06
Volume	381,600
Avg. Volume (20D)	1,915,712
Open	2.08
Previous Close	2.08
Day's Range	2.04 - 2.10
52-Week Range	1.90 - 5.64
Beta	1.28

About CRDF

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CRDF

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CRDF stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Cardiff Oncology Inc. is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

9 months ago

+19.88%

Cardiff Oncology shares are trading higher after P... Unlock content with Pro Subscription

9 months ago

+54.92%

Cardiff Oncology shares are trading higher after the company announced the initial data from its CRDF-004 Phase 2 trial evaluating Onvansertib.

News

1 month ago · fool.com

Cardiff Oncology (CRDF) Q2 Loss Down 19%

1 month ago · benzinga.com

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncolo...

1 month ago · seekingalpha.com

Cardiff Oncology: Data Update Resolves Some Signals

Onvansertib continues to show dose-dependent activity in KRAS-mutated mCRC, with response rates improving up to 49% in the high-dose arm. Recent data are less dramatic than early interim results, refl...

1 month ago · zacks.com

Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.

2 months ago · seekingalpha.com

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. Th...

2 months ago · marketwatch.com

Cardiff Oncology Names Roger Sidhu as Medical Chief

Sidhu joined Cardiff from Treadwell Therapeutics, where he was medical chief and acting chief executive officer. Previously, Sidhu spent nearly 10 years at Amgen.